-transparent.png){kind=logo}
Bioprostheses fabricated from porcine aortic valves are widely used to replace diseased heart valves. Calcification is the principal cause of the clinical failure of these devices. In the present study, inhibition of the calcification of bioprosthetic heart valve cusps implanted subcutaneously in rats was achieved through the adjacent implantation of controlled-release matrices containing the anticalcification agent ethanehydroxydiphosphonate dispersed in a copolymer of ethylene-vinyl acetate. Prevention of calcification was virtually complete, without the adverse effects of retarded bone and somatic growth that accompany systemic administration of ethanehydroxydiphosphonate.
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
January 1986,
ASAIO transactions,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
September 2009,
Biomaterials,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
January 1991,
ASAIO transactions,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
February 1985,
Circulation,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
September 1988,
Journal of pharmaceutical sciences,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
March 2001,
The Journal of thoracic and cardiovascular surgery,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
January 1994,
The Journal of heart valve disease,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
September 1992,
The Journal of heart valve disease,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
May 2001,
The Annals of thoracic surgery,
R J Levy, and
J Wolfrum, and
F J Schoen, and
M A Hawley, and
S A Lund, and
R Langer
December 2004,
Expert opinion on biological therapy,
